A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
A phase 3 trial of Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine and Rituximab in chronic lymphocytic leukaemia, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) is a phase 3 interventional study registered as NCT05624554 by Merck Sharp & Dohme LLC, with 300 participants enrolled, started 2023-03-16 and due to reach its primary completion in 2027-05-19. Interventions recorded: Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab and Truxima.
Similar pages
not linked directly; found by shared links- TrialA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Shares Nemtabrutinib, Rituximab, Chronic lymphocytic leukaemia, Merck & Co. (MSD) and the tag pipeline.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialSafety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Shares Fludarabine, Cyclophosphamide, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Fludarabine, Cyclophosphamide and the tag pipeline.